BTIG Research Reiterates "Buy" Rating for Gain Therapeutics (NASDAQ:GANX)

Key Points

• BTIG Research has reiterated a "Buy" rating for Gain Therapeutics, setting a price target of $9.00, suggesting a potential upside of 341.18% from current levels.
• Similar recommendations from other analysts include a buy rating from HC Wainwright with an $8.00 target and Maxim Group which raised its target from $5.00 to $7.00.
• Despite positive analyst ratings, Gain Therapeutics recently reported disappointing earnings, with an EPS of ($0.19) that missed expectations by $0.02.

Gain Therapeutics (NASDAQ:GANX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $9.00 target price on the stock. BTIG Research's target price points to a potential upside of 341.18% from the stock's current price.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Monday. Maxim Group lifted their price target on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Tuesday, October 7th. Roth Capital dropped their price objective on shares of Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Gain Therapeutics in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Gain Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $7.86.

Gain Therapeutics Trading Up 7.4%

Shares of Gain Therapeutics stock opened at $2.04 on Wednesday. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $3.19. The stock has a market cap of $73.34 million, a P/E ratio of -3.24 and a beta of 0.11. The stock's 50 day simple moving average is $1.78 and its 200-day simple moving average is $1.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.79 and a quick ratio of 1.79.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Analysts predict that Gain Therapeutics will post -1 EPS for the current fiscal year.

Institutional Trading of Gain Therapeutics

A number of institutional investors have recently modified their holdings of GANX. Dauntless Investment Group LLC acquired a new stake in shares of Gain Therapeutics in the first quarter valued at about $240,000. Kovitz Investment Group Partners LLC bought a new position in Gain Therapeutics in the first quarter worth approximately $91,000. Geode Capital Management LLC boosted its holdings in Gain Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock worth $523,000 after acquiring an additional 8,251 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock worth $498,000 after acquiring an additional 80,407 shares in the last quarter. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.